Contributions
Stay tuned—this is where the team’s scientific contributions will be shared.
Accolades
Check back soon to see how this team is being recognized.
Team Fraser
Generating new small molecules for Parkinson’s targets using structure-based discovery and design
We aim to develop novel, IP-free chemical tools for emerging Parkinson’s disease targets prioritized by ASAP using three complementary, activity-agnostic approaches: fragment-based X-ray screening, covalent screening in disease-relevant cell lines, and virtual screening via docking. Our collaborative team is well-positioned for high-throughput protein biochemistry, compound synthesis, and structural biology. We will initially pursue ten structurally tractable targets, with the goal of advancing validated chemical probes (<100 nM potency in cells) for at least five targets by year three. All compounds will be distributed non-restrictively via Enamine to enable broad community use and downstream modulator (inhibitor, activator, allosteric binder) development.
Tags
Artificial intelligenceStructure guided drug design
Our Research Teams
Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.
